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Background. The p38 and c-Jun N-terminal kinase (JNK)
mitogen-activated protein kinase (MAPK) are intracellular sig-
nal transduction pathways involved in the production of inflam-
matory mediators. Little, however, is known about the contribu-
tion of these pathways to renal inflammation, nor the cell types
in which these pathways are activated within normal and in-
flamed kidneys. The aim of this study was therefore to delineate
the pattern and cellular localization of p38 and JNK activation
in normal rat kidney and rat acute and chronic inflammatory
renal disease.
Methods. Normal male Sprague-Dawley rats and groups of
rats given accelerated anti-glomerular basement membrane
(GBM) disease were killed at 3 hours, day 1, day 7, or day
28 and examined for p38 and JNK pathway activation by
Western blotting and immunolocalization of the phosphory-
lated p38 (p-p38) and JNK (p-JNK) kinases.
Results. In terms of glomerular MAPK activation, Western
blotting identified the presence of both p-p38 and p-JNK in nor-
mal glomeruli, localized by immunohistochemistry to podocytes
and epithelial cells of Bowman’s capsule. In anti-GBM disease,
Western blotting showed that p38 activation peaked at 3 hours
and remained elevated above normal throughout the disease
time course. JNK activation (via the 54 kD isoform) likewise in-
creased at 3 hours of anti-GBM disease and remained elevated
throughout disease. At 3 hours, p-p38, but not p-JNK, was local-
ized to neutrophils and glomerular endothelial cells. p-JNK was
localized to glomerular endothelial cells at day 7. Macrophages,
lymphocytes, activated podocytes, and myofibroblasts were pos-
itive for both p-p38 and p-JNK. In terms of tubular MAPK
activation, Western blotting identified p38 and JNK activation
in tubules of normal kidney. Immunostaining showed that most
cortical tubules contained some p-p38 and p-JNK stained cells.
There was a significant increase in tubular p38 activation at 3
hours of anti-GBM disease, followed by increased JNK activa-
tion of the 54 kD isoform from day 7 onward, and the 46 kD
isoform at day 28. Immunostaining of diseased tissue localized
p-p38 and p-JNK to virtually all cortical tubular cells.
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Conclusion. The p38 and JNK MAPK pathways are acti-
vated in glomeruli and tubules of normal kidney. In acute anti-
GBM disease, there was an increase in p38 activation within
glomerular endothelial cells and within infiltrating neutrophils,
suggesting an important role for p38 MAPK in acute inflam-
mation. In progressive anti-GBM disease, p38 and JNK acti-
vation in podocytes, glomerular endothelial cells, infiltrating
macrophages, T cells, and myofibroblasts suggests that both the
p38 and JNK MAPK pathways are important in chronic inflam-
mation and fibrosis. Blockade of these pathways may therefore
be potentially therapeutic in the treatment of acute and chronic
renal inflammation.
Cresentic glomerulonephritis is characterized by acute
renal inflammation, an aggressive condition resulting in
tissue destruction and a loss of renal function, leading to
end-stage renal failure. Leukocyte infiltration and acti-
vation of intrinsic renal cells are prominent in crescentic
disease, with consequent production of various inflam-
matory mediators, including cytokines and chemokines
[1].
The p38 and c-Jun N-terminal kinase (JNK)
mitogen-activated protein kinase (MAPK) pathways are
well-described intracellular signal transduction pathways
critical to cytokine production. These pathways are in-
volved in the transduction of a cell surface signal to the
nucleus resulting in an alteration in the pattern of gene
transcription and the production of inflammatory me-
diators [2–4]. Both pathways are activated by stressors
such as interleukin 1 (IL-1) and tumor necrosis factor-a
(TNF-a) binding to their surface receptors, which leads
via G-coupled and G-independent mechanisms to a rapid
cascade of sequential kinase phosphorylation resulting in
dual phosphorylation of the Tyr-X-Thr motif of the p38
and JNK kinases [5]. Once phosphorylated, p38 and JNK
translocate to the nucleus and activate a variety of tran-
scription factors by phosphorylation [6–9].
Activation of these pathways is important in devel-
opment of the proinflammatory response, as inhibition
of either of these pathways has been shown to suppress
a number of inflammatory conditions. p38 blockade is
effective in the treatment of human endotoxemia and rat
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models of acute lung injury and arthritis [10–12]. JNK
inhibition has recently been shown to be an effective
treatment in a rat model of arthritis [13]. Although con-
sidered central to the inflammatory process, the role of
p38 and JNK in induction and propagation of renal in-
jury is not well understood. Little is known of the re-
lationship between pathway activation and the onset of
the insult, the relative contributions of these pathways
to the early and late inflammatory response in any in-
flammatory disease and the cell types, both intrinsic and
infiltrative, in which these pathways become activated in
situ. We therefore examined the activation and cell spe-
cific localization of the p38 and JNK MAPKs in a rat
model of aggressive inflammatory kidney disease, anti-
glomerular basement membrane (GBM) disease. This is
the first study to compare and contrast the temporal pat-
tern of activation of the p38 and JNK MAPKs in the
inflamed kidney and to localize the pathways to individ-
ual cell types including intrinsic renal cells and infiltrating
leukocytes.
METHODS
Rat model of crescentic glomerulonephritis
Accelerated anti-GBM glomerulonephritis (anti-
GBM disease) was induced in inbred male Sprague-
Dawley rats (140 to 180 g) (Monash Animal
Services, Melbourne, Australia) as described previously
[14]. Briefly, rats were immunized by subcutaneous injec-
tion of 5 mg of sheep IgG in Freunds complete adjuvant
followed 7 days later (day 0) by an intravenous injection
of 5 mL/kg body weight of sheep anti-GBM serum.
Groups of 10 animals were killed at 3 hours, 24 hours,
7 days, or 28 days following anti-GBM serum injection.
Animals were housed in metabolic cages for 24 hours
in order to collect urine at days 0 to 1, 6 to 7, and
27 to 28. All animals were bled when killed. Tissues
were fixed for 4 hours in 4% formalin or 3 hours in
2% paraformaldehyde-lysine-periodate (PLP) and
processed for histopathology analysis. Serum and
urine creatinine were measured using a Dupont ARL
analyzer and urinary protein estimations (in-house
benzasthonium chloride method) were performed by the
Department of Biochemistry, Monash Medical Centre.
Animal experiments were approved by the Monash
Medical Centre Animal Ethics Committee.
Antibodies
The following mouse monoclonal antibodies were used
in this study: anti-phospho p38 (p-p38) (Sigma-Aldrich,
St Louis, MO, USA # M1877) raised against the dual
phosphorylated p38 peptide and recognizing all the
phosphorylated p38 isoforms; anti-phospho JNK (p-
JNK) (Sigma-Aldrich, # J4750) raised against the dual
phosphorylated JNK peptide and recognizing both the
phosphorylated 46 kD and 54 kD isoforms; anti-CD68
recognizing rat macrophages (Serotec, Oxford UK);
anti-a1-tubulin (Sigma-Aldrich); antidesmin recognizing
activated or injured podocytes [15–18] (Dako, Glostrup,
Denmark, # M0760); 1A4, anti-a-smooth muscle actin
(Sigma-Aldrich); RP-1 recognizing the RP-1 antigen
on rat neutrophils (Becton Dickinson, San Diego,
CA, USA); RECA-1 recognizing rat endothelial cells
(Serotec) and W3/13 (anti-CD43) recognizing T lympho-
cytes and granulocytes [19]. Also used was a rabbit an-
tirat podocalyxin antibody recognizing rat podocytes, a
kind gift from Professor Kerjaschki [20]. Horseradish per-
oxidase and alkaline phosphatase–conjugated goat anti-
mouse (or rabbit) IgG, and peroxidase-conjugated mouse
(or rabbit) antiperoxidase complexes (PAP) and alka-
line phosphatase–conjugated mouse antialkaline phos-
phatase complexes (APAAP) were purchased from
Dako. p-p38 and p-JNK peptides were kindly provided
by Cell Signaling Technology (Beverly, MA, USA).
Western blot analysis
At sacrifice, the right kidney from each animal
was dissected and placed immediately into ice cold
phosphate-buffered saline (PBS) and sieved sequentially
through 250 lm, 150 lm, and 75 lm mesh to obtain
glomerular and tubular fractions. The purity of separa-
tion was visually determined to be greater than 95% for
glomeruli and greater than 98% for tubular fragments
by light microscopy. The fractions were centrifuged and
resuspended in 0.5 or 1.0 mL sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer for 5 minutes vortexing every 2 minutes and heated
to 100◦C for 5 minutes. The samples were centrifuged
at 14,000 rpm for 5 minutes and the supernatant was
stored at −80◦C. Protein estimations were performed
using a Bradford assay (Pierce, Rockford, IL, USA).
Glomerular and tubular protein was loaded at 80 ug per
well and separated on a 12.5% SDS-PAGE gel. Gels were
electroblotted onto a polyvinylidine difluoride (PVDF)
membrane, incubated for 4 hours in 20 mL of blocking
buffer (PBS, 5% skim milk), washed three times in wash
buffer (PBS, 0.05% Tween 20, pH7.6), and incubated with
either anti-p-p38 (1 ug/mL) or anti-p-JNK (2 ug/mL)
in 5% bovine serum albumin (BSA) in wash buffer
overnight at 4◦C. Blots were washed three times and
incubated with horseradish peroxidase–conjugated goat
antimouse IgG [1:10,000 in 10% normal rat serum, 1%
normal sheep serum, and 1% fetal calf serum (FCS)] for
2 hours at room temperature. Membranes were washed
three times and the membrane-bound antibody detected
by Supersignal West Pico chemilumescencent substrate
(Pierce) and captured on x-ray film. To determine
the equivalence of protein loading, membranes
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were stripped using ×1 stripping buffer (Chemicon
International, Temecula, CA, USA), blocked with 20 mL
of blocking buffer for 4 hours, then probed with anti-a1-
tubulin (1:5000) in 5% BSA in wash buffer overnight.
Membranes were washed three times and incubated with
horseradish peroxidase–conjugated goat antimouse IgG,
washed in wash buffer three times, and developed with
chemiluminescence (Pierce) and captured on x-ray film.
Densitomety analysis was performed using a Gel Pro
analyzer program (Media Cybernetics, Silver Springs,
MD, USA).
Immunohistochemistry
For p-p38 immunostaining, slices of the left kid-
ney were fixed in 4% buffered formalin, embedded in
paraffin, 4lm sections cut and dewaxed in histosol and
rehydrated. For p-JNK immunostaining, slices of the
left kidney were fixed in PLP, 22-oxacalcitriol (OCT)
embedded and 4 lm sections cut. Two-color immuno-
histochemical staining was performed as described
previously [21]. For both p-p38 and p-JNK immunostain-
ing, the sections were microwave oven heated in Dako
microwave buffer (Dako, # S1700) for 10 minutes, al-
lowed to cool, washed in PBS, and blocked with 10%
normal sheep serum, 10% FCS in PBS for 30 minutes
at room temperature, and incubated overnight at 4◦C
with either anti-p-p38 or anti-p-JNK at 5 ug/mL in 10%
normal rat serum, 1% BSA in PBS. Sections were sub-
sequently washed once in PBS, endogenous peroxidase
inactivated in 1% H2O2 in methanol for 20 minutes, incu-
bated with horseradish peroxidase–conjugated goat anti-
mouse IgG followed by mouse PAP and developed with
3,3-diamenobenzidine to produce a brown color. When
double labeling, the sections were microwave oven
heated, blocked with 10% normal sheep serum and 10%
FCS in PBS and incubated with anti-CD68 at 1 ug/mL,
RP-1 (1:100), W3/13 (1:500), antidesmin (1:100), an-
tipodocalyxin (1:600), RECA-1 (1:100), or 1A4 (1:2000)
overnight at 4◦C in 10% normal rat serum and 1%
BSA. For CD68, W3/13, RP-1, and desmin staining,
the sections were incubated with alkaline phosphatase–
conjugated goat antimouse IgG and mouse APAAP
and developed with Fast Blue BB Salt (Ajax Chemi-
cal, Melbourne, Australia), to produce a blue color. For
1A4, RECA-1, and podocalyxin staining, sections were
inactivated in 1% H2O2 in methanol for 20 minutes,
incubated with horseradish peroxidase–conjugated goat
antimouse (or rabbit) IgG followed by mouse (or rab-
bit) PAP and developed with Vector SG (Vector Labo-
ratories, Burlingame, CA, USA) to produce a gray color.
Sections were either counterstained with periodic acid-
Schiff (PAS) reagent or left uncounterstained and
mounted with glycerol medium.
In addition to replacement of the primary antibod-
ies with irrelevant isotype-matched control antibodies
in the staining protocol, specificity of p-p38 and p-JNK
immunostaining was demonstrated by incubating the
anti-p-p38 antibody or anti-p-JNK antibody with a ten-
fold molar excess of the p-p38 or p-JNK peptides for
30 minutes at room temperature prior to application to
tissue sections. Incubation of the p-p38 antibody with
the p-p38, but not the p-JNK, peptide abolished the
p-p38 staining pattern. Incubation of the p-JNK anti-
body with the p-JNK, but not the p38 peptide, abolished
the p-JNK staining pattern. Quantitation of p-p38 and
p-JNK immunostaining in RECA-1–positive endothe-
lial cells and podocalyxin-positive podocytes was per-
formed by counting the number of double stained cells on
20 glomerular cross-sections (gcs) per animal on blinded
slides.
Statistical analysis
Data are presented as mean ± 1 SD. Comparisons
were made between groups of animals by the analysis of
variance (ANOVA), using the Bonferroni correction for
multiple comparisons (GraphPad Software, San Diego,
CA, USA).
RESULTS
Characterization of rat anti-GBM glomerulonephritis
Administration of anti-GBM serum to primed rats
resulted in a severe glomerulonephritis in which ani-
mals developed heavy proteinuria (Fig. 1A) and a loss
of renal function (Fig. 1B). Renal histology showed the
development of crescentic glomerulonephritis with 32%
of glomeruli exhibiting crescents on day 28 (Fig. 1).
Hypercellularity, leucocyte infiltration, glomerular PAS
deposits, and tubular damage were also evident.
p-p38 and JNK activation in normal rat kidney
Western blotting of normal rat kidney demonstrated
activation of the p38 MAPK pathway in both glomeruli
and tubules (Fig. 2A and B). p-p38 immunostaining was
present in normal glomeruli in a nuclear pattern and was
localized mainly to podocytes and parietal epithelial cells
of Bowman’s capsule (Figs. 3A and 4A), although en-
dothelial cells were also occasionally stained (data not
shown). Most cortical tubular cross-sections showed the
presence of one or more cells stained for p-p38 (Fig. 5A).
The JNK MAPK pathway was also activated within both
glomeruli and tubules of the normal rat kidney, as demon-
strated by Western blotting, with activation of the 46 kD
isoform (pJNK46) predominant over the 54 kD isoform
(pJNK54) (Fig. 2C and D). p-JNK immunostaining was
present within glomeruli in a nuclear distribution and was
localized mainly to podocytes and parietal epithelial cells
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Fig. 1. Proteinuria, renal failure, and cresent
formation in rat anti-glomerular basement
membrane (GBM) disease. Compared to nor-
mal (), animals with anti-GBM disease ()
had a progressive rise in (A) proteinuria and
(B) serum creatinine (∗P < 0.05; ∗∗P < 0.001;
∗∗∗P < 0.001 vs. normal) consistent with re-
nal injury. Periodic acid-Schiff (PAS) staining
showed that compared to normal rat kidney
(C), day 28 of anti-GBM disease (D) exhib-
ited glomerular crescent (c) formation with
PAS deposits and obliteration of Bowman’s
space (magnification ×250).
of Bowman’s capsule (Figs. 3B and 4B). p-JNK immunos-
taining was also present in many tubular cells within the
cortex (Fig. 5B).
Glomerular p38 and JNK activation in rat
anti-GBM disease
By Western blotting, there was a peak ninefold increase
in glomerular p-p38 at 3 hours after induction of the dis-
ease with a two- to threefold increase in p-p38 compared
to normal at days 1, 7, and 28 (Fig. 2A). Glomerular acti-
vation of the JNK pathway also occurred early, as a conse-
quence of phosphorylation of the 54 kD isoform with an
18-fold increase at 3 hours. However, unlike p-p38, there
was an increase in phosphorylation with disease progres-
sion with a 32-fold increase of p-JNK54 above normal
at day 28. Glomerular activation of the JNK MAPK
pathway is almost exclusively via phosphorylation of the
54 kD isoform; phosphorylation of the 46 kD isoform
remained unchanged throughout the time-course of the
disease (Fig. 2C).
Within 3 hours of induction of anti-GBM disease, there
was a substantial increase in glomerular p-p38 immunos-
taining, consistent with Western blot data. There was
approximately a fivefold increase in the number of
glomerular p-p38–positive cells (Figs. 3C and 6A), which
remained elevated at both day 7 and day 28 (Figs. 3E
and 6A). The number of glomerular p-JNK–positive cells
was not increased at 3 hours of the disease, inconsis-
tent with the Western blot data; however, there was a
progressive increase in the number of p-JNK–positive
cells from day 1 following induction of the disease, such
that there was a fourfold increase by day 28 (Figs. 3F
and 6B).
Specificity of p-p38 and p JNK immunostaining
Antibody specificity was determined by incubating
the antibodies with either the p-p38 and p-JNK pep-
tides prior to immunostaining of tissue. Incubation of
the anti-p-p38 antibody with the p-p38 peptide (Fig. 3G),
but not the p-JNK peptide (not shown), abrogated
p-p38 staining. Likewise, incubation of the anti-p-
JNK antibody with the p-JNK peptide (Fig. 3H), but
not the p-p38 peptide (not shown) abrogated p-JNK
staining.
Inflammatory cells: p-p38 and p-JNK
immunolocalization
The presence of p-p38 and p-JNK within infiltrating
inflammatory cells was examined. Virtually all neu-
trophils, the predominant inflammatory cell within the
glomerulus at 3 hours, exhibited nuclear p-p38 (Fig. 7A),
but not p-JNK (Fig. 7B), staining suggesting that the early
peak of p-p38 identified by Western blotting may be in
part as a result of extensive neutrophil infiltration. Exten-
sive glomerular and interstitial macrophage infiltration
occurs with progression of the disease. Both p-p38 and
p-JNK immunostaining was present within macrophages
(Fig. 7C and D), infiltrating the interstitium, glomerular
tuft and fibrocellular crescents (data not shown). In order
to determine whether macrophages express p-p38 or
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Fig. 2. Expression of phospho p38 (p-p38) and phospho JNK (p-JNK) in glomeruli and tubules in rat crescentic glomerulonephritis. Glomeruli
(A and C) and tubules (B and D) were isolated from normal rats and from rats at 3 hours, 1 day, 7 days, or 28 days following the induction of
anti-glomerular basement membrane (GBM) disease and probed for p-p38 (A and B), and p-JNK (C and D) by Western blotting. Blots were
stripped and probed for a1-tubulin as a loading control. Two representative animals are shown at each time point. Graphs show densiometric
analysis (mean ± 1 SD, groups of ten animals) of the ratio of p-p38 (A and B) or p-JNK (C and D) to a1-tubulin compared to normal animals
(assigned a p-p38 or p-JNK to a1-tubulin ratio of 1). ∗P < 0.05; ∗∗P < 0.001 vs. normal.
p-JNK during early recruitment, we examined
macrophage infiltration at 3 hours. Dual staining of
macrophages with both p-38 and p-JNK suggests acti-
vation of macrophages throughout the disease course
occurs via both stress-activated pathways (data not
shown). In addition, both interstitial and glomerular
lymphocytes at day 28 were positive for p-p38 and p-JNK
immunostaining (Fig. 7E and F).
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Fig. 3. Localization by immunohistochemistry of phosphorylated p38 (p-p38) and phosphorylated JNK (p-JNK) in normal and diseased glomeruli.
Normal rat glomeruli demonstrated nuclear staining of p-p38 (A) in many glomerular cells, including podocyte-like cells (arrowheads), in addition
to parietal epithelial cells of Bowman’s capsule (arrow). Within 3 hours of intravenous injection of nephrotoxic serum, there is a substantial increase
in p-p38 (C), which remained elevated at day 28 (E). Glomerular and tubular p-p38 (G) immunostaining of tissue of day 28 anti-glomerular
basement membrane (GBM) disease was abrogated following incubation of the anti-p-p38 antibody with the p-p38 peptide. Normal rat glomeruli
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Fig. 4. Immunolocalization of phosphory-
lated p38 (p-p38) and phosphorylated JNK
(p-JNK) to podocytes in normal rat glomeruli.
Normal rat glomeruli were immunostained
for podocytes (gray) using a podocalyxin
marker. Podocyte nuclei were positive for (A)
p-p38 (brown, arrowheads) and (B) p-JNK
(brown, arrowheads) (magnification ×1200).
Fig. 5. Localization by immunohistochem-
istry of phosphorylated p38 (p-p38) and
phosphorylated JNK (p-JNK) in normal
and diseased tubules. In normal cortex (A)
most tubular cross-sections showed p-p38 im-
munostaining (brown) of one of more ep-
ithelial cells. p-JNK was also present in
many tubular cells (B) of normal cortex. At
3 hours of anti-glomerular basement mem-
brane (GBM) disease, there was an increase
in p-p38 staining of most cortical tubular cells
(C, brown), which persisted to day 28 of dis-
ease (E, brown). In contrast, there was no in-
crease in tubular immunostaining of p-JNK at
3 hours of anti-GBM disease (D, brown); how-
ever, virtually all tubular cells were positive at
day 28 of disease (F, brown) [magnification (A
to D) ×400; (E and F) ×250].
demonstrated nuclear staining of p-JNK (B) in podocyte-like cells (arrowheads) and parietal epithelial cells of Bowman’s capsule (arrow). At
3 hours anti-GBM disease, there was no apparent increase in glomerular p-JNK immunostaining (D). However p-JNK staining was increased
1 day following induction of anti-GBM disease, and at day 28 (F). Glomerular and tubular p-JNK (H) immunostaining of tissue of day 28 anti-GBM
disease was abrogated following incubation of the anti-p-JNK antibody with the p-JNK peptide [magnification (A to F) ×400; (G and H) ×250].
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Fig. 6. Quantitification of phosphorylated p38 (p-p38) and phospho-
rylated JNK (p-JNK) immunostaining in rat anti-glomerular basement
membrane (GBM) disease. Normal animals () and animals given anti-
GBM disease () were killed at 3 hours, 1 day, 7 days, or 28 days. (A)
The number of glomerular cells stained for p-p38 was increased at
3 hours following induction of anti-GBM disease and remained elevated
throughout the disease time-course. (B) The number of glomerular cells
positive for p-JNK was increased at day 1 and progressively increases
to day 28 of anti-GBM disease. The data show the mean number of
positive cells/glomerular cross-section (gcs) ± 1 SD. ∗P < 0.05; ∗∗P <
0.001 vs. normal, groups of ten animals.
Intrinsic glomerular cells: p-p38 and p-JNK
immunolocalization
In normal glomeruli, occasional endothelial cells were
positive for both p-p38 and p-JNK (data not shown); how-
ever, at 3 hours following induction of disease, endothelial
p-p38 (Figs. 8A and 9A), but not p-JNK immunostaining
was substantially increased and remained elevated at all
subsequent time points. By day 7, however, endothelial
p-JNK immunostaining was increased (Figs. 8B and 9A)
and remained elevated at day 28. In addition, there was
an increase in the number of both p-p38 and p-JNK–
positive podocytes during the development of anti-GBM
disease (Fig. 9). An increase in podocytic desmin stain-
ing is a well-recognized marker of injured or activated
podocytes [15–18]. Double immunohistochemistry iden-
tified that many injured or activated podocytes (desmin-
positive cells) were positive for p-p38 and p-JNK (Fig. 8C
and D).
Myofibroblasts express p-p38 and p-JNK
Interstitial and glomerular fibrosis is a feature of
chronic anti-GBM disease at day 28. Both p-p38 and
p-JNK were localized to glomerular (including within
fibrocellular crescents) and interstitial myofibroblasts, by
double immunhistochemical staining for a-smooth mus-
cle actin, a cytoplasmic marker of myofibroblasts (Fig. 8E
and F).
Tubular p38 and JNK activation in rat anti-GBM disease
Western blotting demonstrated an early four- to sixfold
increase in tubular p-p38 at 3 hours anti-GBM disease and
this persisted with progression of the disease (Fig. 2B).
In contrast, there was no increase in activation of the
JNK MAPK pathway until day 7 of anti-GBM disease.
This was due to increased p-JNK54 at day 7, and a
threefold and sixfold increase of p-JNK46 and p-JNK54,
respectively, at day 28 (Fig. 2D).
Immunostaining identified a substantial increase in
p-p38 immunostaining in cortical tubules at 3 hours of
anti-GBM disease, and this remained evident throughout
the disease time course (Fig. 5C and E). Tubular p-JNK
immunostaining was not different to normal at 3 hours
or day 1 of anti-GBM disease, but was substantially
increased in all tubules (both well preserved and dam-
aged) on days 7 and 28 (Fig. 5D and F).
DISCUSSION
Activation of the p38 and JNK pathways has been
described previously in glomerular lysates of acute rat
anti-GBM disease [22, 23]. However, no studies to date
have compared the activation of these MAPK pathways
in glomeruli versus tubules, nor clearly identified the cell
types in which these pathways are activated in normal or
diseased kidney. We have confirmed activation of p-p38
in acute anti-GBM disease and identified both similari-
ties and differences with regard to the activation of the
p38 and JNK pathways with progression of the disease in
both the glomerular and tubulointerstitial compartments.
In normal rat kidney, p38 and JNK MAPK pathway
activation is present within podocytes, parietal cells of
Bowman’s capsule, and most tubules of the cortex. JNK
activation of the 46 kD isoform predominated over acti-
vation of the 54 kD isoform in both glomeruli and tubules.
The physiologic role for these pathways in normal rat kid-
ney is not understood and the triggers for dual pathway
activation in podocytes and cortical tubules are unknown,
but may be related to their functions of selective filtration
and solute reabsorption, respectively. Therefore, block-
ade of the p38 or JNK MAPK pathways could potentially
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Fig. 7. Immunolocalization of phosphorylated p38 (p-p38) and phos-
phorylated JNK (p-JNK) to infiltrating leukocytes in rat crescentic
glomerulonephritis. At 3 hours following induction of disease, infiltrat-
ing neutrophils (A and B; blue) express p-p38 (A, brown; arrowheads)
but not p-JNK (B, brown; arrowheads). Infiltrating macrophages (C
and D; blue) and T lymphocytes (E and F; blue) at day 28 anti-GBM
disease express both p-p38 (C and E; brown; arrowheads) and p-JNK
(D and F; brown; arrowheads) (magnification ×800).
result in deleterious changes in normal renal function.
Previous studies have found p-JNK staining of podocytes
and distal tubules in normal rat kidney [24] and p-p38
staining in glomeruli in rat crescentic glomerulonephritis
[25]. However, the p-p38 and p-JNK staining pattern in
these studies is non-nuclear. We demonstrated the pres-
ence of the activated kinases within nuclei of these cell
types in normal and diseased kidney. The nucleus is the
expected location of p38 and JNK after phosphorylation
and we confirmed the specificity of immunostaining by
the use of blocking phospho peptides. The reason for
the difference in staining pattern with these studies is
not clear, but may relate to fixation conditions or the
immunohistochemistry techniques used.
The p38 MAPK pathway was activated within both
glomeruli and tubules in the acute phase of anti-GBM
disease and remained activated throughout the disease
course. The JNK MAPK pathway was also activated in
glomeruli in acute anti-GBM disease and thereafter in-
Fig. 8. Immunolocalization of phosphorylated p38 (p-p38) and phos-
phorylated JNK (p-JNK) to endothelial cells, podocytes, and myofi-
broblasts in rat anti-glomerular basement membrane (GBM) disease.
Endothelial cells (A and B; gray) were immunostained for (A) p-p38
(brown; arrowheads) at 3 hours and (B) p-JNK (brown; arrowheads)
at day 7 following induction of anti-GBM disease. Activated podocytes
identified by desmin staining (C and D; blue) express both (C) p-p38
(brown; arrowheads) and (D) p-JNK (brown; arrowheads) at 28 days
following induction of anti-GBM disease. Myofibroblasts identified by
a-smooth muscle actin staining (E and F; gray) are immunostained for
(E) p-p38 (brown; arrowheads) as well as (F) p-JNK (brown; arrow-
heads) at day 28 anti-GBM disease (magnification ×1000).
creased progressively; however, in contrast to the p38
pathway, JNK activation was not increased in tubules un-
til late in the course of disease. These temporal differ-
ences with respect to activation in glomeruli and tubules
raise the possibility that p38 MAPK is important as an
early or acute inflammatory signal transduction pathway
and that JNK MAPK is important in late or chronic in-
flammation.
Although we could demonstrate an increase in
glomerular JNK activation at 3 hours by Western blot-
ting, there was no apparent increase in the number of
glomerular cells stained for p-JNK at this time point.
Since there was no change in tubular JNK activation at
3 hours, the increase in glomerular JNK activation seen
by Western blotting could not be due to tubular con-
tamination (<5%) of the glomerular preparations. The
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Fig. 9. Quantification of phosphorylated p38 (p-p38) and phospho-
rylated JNK (p-JNK)–positive endothelial cells and podocytes in rat
anti-glomerular basement membrane (GBM) disease. The number
of RECA-1–positive endothelial cells (A) and podocalyxin-positive
podocytes (B) double stained for p-p38 () or p-JNK () was assessed
in glomeruli of normal animals and animals 3 hours, 1 day, 7 days, and
28 days following induction of anti-GBM disease. The data are rep-
resented as the mean ± SD number of positive cells per glomerular
cross-section (gcs) for groups of 10 animals. ∗P < 0.05; ∗∗∗P < 0.001
compared with normal animals.
discrepancy may be explained by a marked increase in
JNK activation within the cells that already have some
level of JNK activity in the normal glomerulus. Since the
immunostaining technique uses substantial signal ampli-
fication, it is a semiquantitative rather than a quantitative
technique and as such the signal generated is not propor-
tional to the amount of antigen present.
In acute anti-GBM disease, the rapid increase in
glomerular p-p38 seen at 3 hours was due to the ac-
tivation of the pathway within podocytes, endothelial
cells, infiltrating neutrophils, and tubular cells, whereas
JNK activation was confined to podocytes. Podocytes be-
come activated, either as a direct consequence of the
initial glomerular insult or as a result of the inflam-
matory cytokine milieu produced by infiltrating neu-
trophils and macrophages. Podocytes themselves are an
important source of IL-1 generation in rat crescentic
nephritis [26–29]; however, the intracellular signaling
mechanisms leading to podocyte activation are not under-
stood. Activation of the p38 MAPK pathway in podocytes
has been linked with apoptosis, but is not known to occur
in resting podocytes [30]. This is the first demonstration
of p38 and JNK activation within podocytes in diseased
kidney.
p38 and JNK MAPK activation have previously been
shown to be important in endothelial cell expression of cy-
tokines and adhesion molecules in vitro [31–35]. We have
demonstrated in an in vivo inflammatory model acute en-
dothelial p38 activation and late or chronic endothelial
JNK activation. Furthermore, activation of the p38, but
not the JNK, MAPK was seen within neutrophils at this
early time point. This differential staining pattern sug-
gests that neutrophils become activated at least in part
via the p38 but not the JNK MAPK pathway. This is
consistent with in vitro studies that have demonstrated
the importance of p38 activation to neutrophil functions
such as chemotaxis, superoxide generation, cytokine pro-
duction, adhesion, and degranulation [36–39] and that
cytokines, chemotactic factors, and mitogens fail to stim-
ulate JNK pathway activation within neutrophils, despite
the presence of the JNK kinase [40, 41]. Our findings
support a role for p38, but not JNK activation in acute
renal inflammation. This is consistent with a study using a
novel immunosuppressant drug with activity against the
p38 pathway, which inhibited acute renal injury in the
Wistar Kyoto (WKY) model of anti-GBM disease [42].
In chronic anti-GBM disease, p-p38 and JNK acti-
vation occurred in intrinsic glomerular cells such as
activated podocytes and endothelial cells in addition to
infiltrating macrophages, lymphocytes, and myofibrob-
lasts. p-p38 and p-JNK colocalize to macrophages and
lymphocytes within the glomerular tuft, glomerular cres-
cent, and interstitium. One previous report has localized
nuclear p-p38 to glomeruli in human cresentic glomeru-
lonephritis, although the cell types stained positive for
p-p38 were not described [43]. Activation of the p38 and
JNK kinases has been demonstrated in vitro to be critical
for macrophage and lymphocyte activation, and the pro-
duction of proinflammatory cytokines [44–52]. Our study
confirms p38 and JNK MAPK activation in these cell
types in an in vivo inflammatory model. The presence of
p38 and JNK MAPK activation in myofibroblasts during
the sclerotic phase of the disease supports recent in vitro
evidence that transforming growth factor-b (TGF-b1)
induced fibrosis is in part dependent on activation of these
pathways [53–56], and treatment with a p38 inhibitor has
been shown to reduce fibrosis in a rat model of toxic lung
injury [11]. Dual staining of macrophages, T cells, and
myofibroblasts in progressive disease suggests a role for
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both pathways in chronic inflammation and fibrosis, and
the propagation of renal injury.
This study has identified differential tubular activation
of the p38 and JNK pathways at different stages of the
inflammatory process. Tubular activation of p38 MAPK
is increased in the acute phase of disease and involves
all cortical tubular segments. In contrast, the increase in
tubular JNK pathway activation occurs later in the dis-
ease, with a detectable increase in phosphorylation at
days 7 and 28 anti-GBM disease, with all cortical tubular
segments involved. Tubular epithelial cells are known to
produce a variety of inflammatory mediators when stim-
ulated and contribute to the development of interstitial
injury. In vitro studies of human proximal convoluted
tubular cells have demonstrated that IL-6 and TNF-a
production is p38 dependent [57–59]. Furthermore, in this
same cell type, arachidonic acid has been shown to stimu-
late phosphorylation of both the JNK and p38 MAPK and
hyperglycaemia can induce phosphorylation of p38 and
stimulate production and secretion of angiotensinogen
in vitro [60–62]. Differential activation of these pathways
in tubular cells within an in vivo inflammatory model has
not been previously described and no studies to date have
identified a role for these signal transduction pathways in
tubular cells within renal disease.
We have demonstrated activation of the p38 and JNK
MAPK pathways in both glomeruli and tubules within
normal kidney and in accelerated crescentic glomeru-
lonephritis. Some of the differences in activation of the
pathways relate to the changes in the nature of the in-
filtrating leukocytes involved in renal injury, as well as
temporal differences in activation in endothelial and
tubular cells. Our findings suggest that the p38 pathway
may be important in the acute phase of anti-GBM dis-
ease, whereas both the p38 and JNK pathways may be
important in chronic anti-GBM disease. Inhibition of
these stress activated pathways, therefore, has the poten-
tial to affect different stages of the disease process, and
single or dual blockade of the p38 and the JNK MAPK
pathways becomes an attractive treatment option for
inflammatory kidney disease.
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